Publicacións nas que colabora con María Belén Vidriales Vicente (17)

2024

  1. Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient

    Biomedicines, Vol. 12, Núm. 1

2020

  1. Biological features and prognostic impact of bone marrow infiltration in patients with diffuse large b-cell lymphoma

    Cancers, Vol. 12, Núm. 2

  2. Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic

    Frontiers in Medicine, Vol. 7

2017

  1. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy*

    Leukemia and Lymphoma, Vol. 58, Núm. 5, pp. 1144-1152

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

2014

  1. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Leukemia, Vol. 28, Núm. 2, pp. 391-397

  2. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

    Leukemia Research, Vol. 38, Núm. 5, pp. 551-556

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2011

  1. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

    Leukemia, Vol. 25, Núm. 4, pp. 697-706

  2. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells

    Clinical Cancer Research, Vol. 17, Núm. 7, pp. 1692-1700

2010

  1. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients

    Haematologica, Vol. 95, Núm. 5, pp. 745-751

2009

  1. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

    Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709

  2. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies

    American Journal of Hematology, Vol. 84, Núm. 3, pp. 149-152

  3. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152

2002

  1. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

    Leukemia, Vol. 16, Núm. 8, pp. 1423-1431

1997

  1. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

    Blood, Vol. 90, Núm. 6, pp. 2465-2470

  2. Trasplante autólogo con esquema BEAM en linfoma

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 46-49